Assessment of genomic alterations in non-syndromic von Hippel-Lindau: Insight from integrating somatic and germline next generation sequencing genomic data

Danielle K Manning; Priyanka Shivdasani; Diane R Koeller; Alison Schwartz; Huma Q Rana; Judy E Garber; Neal I Lindeman; Arezou A Ghazani

doi:10.1016/j.dib.2021.107653

Assessment of genomic alterations in non-syndromic von Hippel-Lindau: Insight from integrating somatic and germline next generation sequencing genomic data

Data Brief. 2021 Dec 1:39:107653. doi: 10.1016/j.dib.2021.107653. eCollection 2021 Dec.

Authors

Danielle K Manning¹, Priyanka Shivdasani¹, Diane R Koeller², Alison Schwartz², Huma Q Rana^{2

3

4

5}, Judy E Garber^{2

3

4

5}, Neal I Lindeman^{1

5}, Arezou A Ghazani^{1

5

6}

Affiliations

¹ Department of Pathology, Brigham and Women's Hospital, Boston, MA, United States.
² Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, Massachusetts, United States.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States.
⁴ Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, United States.
⁵ Harvard Medical School, Boston, Massachusetts, United States.
⁶ Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States.

Abstract

Von Hippel-Lindau (VHL) syndrome is a hereditary cancer genetic condition associated with inactivating pathogenic alterations in the VHL tumor suppressor gene located at 3p (short arm of chromosome 3). Classic features of VHL include clear cell renal cell carcinoma, hemangioblastomas of the brain, spinal cord, and retina, pheochromocytoma, pancreatic cysts, and neuroendocrine tumors. Two sets of genomic information may be available from patients with VHL: the germline data showing the constitutional genetic profile and somatic profile obtained from patient tumor(s). Here we present both somatic and germline dataset from heterozygous carriers of germline VHL variants who exhibit non-syndromic VHL phenotypes. This data description article accompanies the paper "Pathogenicity of VHL variants in families with non-syndromic von Hippel-Lindau phenotypes: an integrated evaluation of germline and somatic genomic results'' by Huma Q. Rana, Diane R. Koeller, Alison Schwartz, Danielle K. Manning, Katherine A. Schneider, Katherine M. Krajewski, Toni K. Choueiri, Neal I. Lindeman, Judy E. Garber, Arezou A. Ghazani. We provide next generation sequencing (NGS) data obtained from DNA from tumors (renal cancer, bladder cancer, and cerebral hemangioblastoma) of three VHL carriers. The somatic dataset was analyzed for single nucleotide variants (SNVs) and copy number variants (CNVs) in 447 cancer genes, and structural variation (SVs) in 191 regions across 60 genes for rearrangements. We also present germline raw NGS data and analyzed SNV and CNV data in exonic regions of 133 hereditary cancer genes obtained from the peripheral blood of two VHL carriers.

Keywords: Hemangioblastoma; Matched tumor-germline data; Next generation sequencing; Renal cell carcinoma; VHL gene; Von Hippel-Lindau.